| Literature DB >> 35745601 |
Noura Hazime1,2, Yanath Belguesmia2, Isabelle Kempf3, Alexandre Barras1, Djamel Drider2, Rabah Boukherroub1.
Abstract
Bacterial resistance to antibiotics has become a major public health problem worldwide, with the yearly number of deaths exceeding 700,000. To face this well-acknowledged threat, new molecules and therapeutic methods are considered. In this context, the application of nanotechnology to fight bacterial infection represents a viable approach and has experienced tremendous developments in the last decades. Escherichia coli (E. coli) is responsible for severe diarrhea, notably in the breeding sector, and especially in pig farming. The resulting infection (named colibacillosis) occurs in young piglets and could lead to important economic losses. Here, we report the design of several new formulations based on colistin loaded on alginate nanoparticles (Alg NPs) in the absence, but also in the presence, of small molecules, such as components of essential oils, polyamines, and lactic acid. These new formulations, which are made by concomitantly binding colistin and small molecules to Alg NPs, were successfully tested against E. coli 184, a strain resistant to colistin. When colistin was associated with Alg NPs, the minimal inhibition concentration (MIC) decreased from 8 to 1 µg/mL. It is notable that when menthol or lactic acid was co-loaded with colistin on Alg NPs, the MIC of colistin drastically decreased, reaching 0.31 or 0.62 µg/mL, respectively. These novel bactericidal formulations, whose innocuity towards eukaryotic HT-29 cells was established in vitro, are presumed to permeabilize the bacterial membrane and provoke the leakage of intracellular proteins. Our findings revealed the potentiating effect of the Alg NPs on colistin, but also of the small molecules mentioned above. Such ecological and economical formulations are easy to produce and could be proposed, after confirmation by in vivo and toxicology tests, as therapeutic strategies to replace fading antibiotics.Entities:
Keywords: Escherichia coli; alginate nanoparticles; antimicrobial activity; colistin; essential oils; lactic acid; polyamines
Year: 2022 PMID: 35745601 PMCID: PMC9227550 DOI: 10.3390/ph15060682
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
MIC of colistin alone and in combination with Alg NPs against different E. coli strains.
| Strains | Colistin | Alg NPs+Colistin |
|---|---|---|
| 8 | 1 | |
| 8 | 4 | |
| 16 | 4 | |
| 16 | 4 | |
| 2 | 1 | |
| 1 | 1 | |
| 2 | 1 | |
| 2 | 2 | |
| 2 | 2 | |
| 1 | 0.5 |
MIC of colistin (in µg/mL) alone and in combination with Alg NPs and components of essential oils against Escherichia coli 184 strain.
| Formulations | MIC |
|---|---|
| Alg NPs+Menthol (500:10) | - |
| Alg NPs+Carvacrol (500:10) | - |
| Alg NPs+Farnesol (500:10) | - |
| Alg NPs+Geraniol (500:10) | - |
| Alg NPs+Colistin+Menthol (500:40:10) | 0.31 |
| Alg NPs+Colistin+Carvacrol (500:40:10) | ≤0.62 |
| Alg NPs+Colistin+Farnesol (500:40:10) | ≤1.25 |
| Alg NPs+Colistin+Geraniol (500:40:10) | ≤1.25 |
-: No inhibition.
MIC of colistin (in µg/mL), alone and in combination with Alg NPs and lactic acid, against Escherichia coli 184 strain.
| Formulation | MIC |
|---|---|
| Lactic acid (15) | - |
| Alg NPs+Colistin (500:40) | 1.25 |
| Alg NPs+Colistin+Lactic acid (500:40:15) | ≤0.62 |
-: No inhibition.
MIC of colistin (in µg/mL), alone and in combination with Alg NPs and polyamines, against Escherichia coli 184 strain.
| Formulation | MIC |
|---|---|
| Colistin | 8 |
| ACS Alg NPs+Colistin+Spermine (500:60:20) | 5 |
| ACSd: Alg NPs+Colistin+Spermidine (500:60:20) | 2.5 |
| ACP: Alg NPs+Colistin+Piperazine (500:60:20) | 10 |
| ACSd1: Alg NPs+Colistin+Spermidine (500:30:30) | 3.75 |
| ACSd2: Alg NPs+Colistin+Spermidine (500:20:40) | 5 |
| ACSd3: Alg NPs+Colistin+Spermidine (500:10:50) | 5 |
Figure 1Escherichia coli 184 intracellular proteins leakage after treatments with colistin (8 µg/mL), Alg NPs (500 µg/mL), and Alg NPs+Colistin (500:60 µg/mL).
MIC vs. MBC values of colistin in the different formulations tested against Escherichia coli 184.
| Formulation | MIC | MBC | MBC/MIC |
|---|---|---|---|
| Colistin | 8 | 8 | 1 |
| Alg NPs+Colistin (500:40) | 1.25 | 5 | 4 |
| Alg NPs+Colistin+Menthol (500:40:10) | 0.31 | 0.62 | 2 |
| Alg NPs+Colistin+Lactic acid (500:40:15) | ≤0.62 | 1.25 | 2 |
Figure 2Killing curves of Escherichia coli 184 treated with different formulations of colistin associated with Alg NPs and menthol or lactic acid.
Figure 3TEM micrographs of Escherichia coli 184 cells treated with (A–C) control; (D) Alg NPs (500 µg/mL); (E–F) Colistin (8 µg/mL); (G–H) Alg NPs+Colistin (500:1.25) µg/mL; (I–J) Alg NPs+Colistin+Lactic acid (500:0.62:15) µg/mL; (K–L) Alg NPs+Colistin+Menthol (500:0.31:10) µg/mL.
MIC values of colistin (µg/mL), alone and upon association with Alg NPs and lactic acid or menthol, on Escherichia coli 184 (mcr-1) strain after treatment mimicking the passage through the gastrointestinal tract.
| Formulation | Untreated | Incubation at pH 3 for 30 min and then at pH 6 for 2 h | Incubation at pH 3 for 30 min with Pepsin * and then at pH 6 for 2 h | Incubation at pH 3 for 30 min with Pepsin * and then at pH 6 for 2 h with |
|---|---|---|---|---|
| Colistin (60 µg/mL) | 8 | 8 | 8 | ≥32 |
| Alg NPs+Colistin (500:40) µg/mL) | 1.25 | 1.25 | 5 | 5 |
| Alg NPs+Colistin+Lactic acid (500:40:10 µg/mL) | 0.62 | 1.25 | 2.5 | 2.5 |
| Alg NPs+Colistin+Menthol (500:40:10) µg/mL | 0.31 | 1.25 | 1.25 | 2.5 |
* Pepsin: 15 U/mL; trypsin: 40 U/µL; chymotrypsin: 5 U/mL.
Figure 4Cytotoxicity of the different colistin formulations on HT-29 cells.
Figure 5Cytotoxicity of colistin, Alg NPs, and components of essential oil formulations on HT-29 cells.
Figure 6Cytotoxicity of lactic acid and Alg NPs+Colistin+Lactic acid formulation on HT-29 cells.
Figure 7Cytotoxicity of colistin, Alg NPs, and spermine and their combinations on HT-29 cells.
E. coli strains used in this study.
| Strains | Origin | Characteristics |
|---|---|---|
| Résapath network *, | Colistin R, ( | |
| ANSES ** collection, | Colistin R, ( | |
| ANSES collection | Colistin S | |
| ANSES collection | Colistin S | |
| ATCC collection | Colistin S, reference strain | |
| Pasteur Institute collection (Paris, France) | Colistin S, reference strain | |
| Pasteur Institute collection (Paris, France) | Strain with truncated LPS | |
| ANSES collection | In vitro resistant variant to colistin | |
| ANSES collection | In vitro resistant variant to colistin | |
| Invitrogen ® | Modified strain (LPS-) |
* French Résapath network for the surveillance of antimicrobial resistance in pathogenic bacteria of animal origin: https//www.resapath.anses.fr/ (accessed 23 May 2022). ** ANSES: French agency for food, environmental, and occupational health and safety. Colistin R: resistance to colistin (minimal inhibitory concentration (MIC) > 2 mg/L). Colistin S: susceptible to colistin (MIC ≤ 2 mg/L).